Document Detail


Efficacy and safety of allopurinol in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency.
MedLine Citation:
PMID:  17697859     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency is a genetic disease of purine metabolism resulting in uric acid overproduction. Allopurinol, which inhibits the enzyme xanthine oxidase and reduces uric acid synthesis, is widely used for the treatment of gout and uric acid overproduction. The aim of the study was to analyze the long-term efficacy and safety of allopurinol in patients with HPRT deficiency. Nineteen patients (13 with Lesch-Nyhan syndrome and 6 with partial HPRT deficiency) were treated with allopurinol (mean dose, 6.4 mg/kg body weight per day; range, 3.7-9.7 mg/kg body weight per day) and followed up for at least 12 months (mean follow-up, 7.6 years). The efficacy of allopurinol was evaluated by serial measurement of purine metabolic parameters and renal function as well as by clinical manifestations. Safety was assessed by recording adverse events. Treatment with allopurinol normalized serum urate level in all patients and resulted in a mean reduction in serum urate of 47%. Allopurinol treatment was associated with a mean 74% reduction in urinary uric acid-to-creatinine ratio. In contrast, allopurinol treatment increased mean hypoxanthine and xanthine urinary excretion rates 5.4- and 9.5-fold, respectively, compared with baseline levels. The decrease in uric acid excretion in complete and partial HPRT-deficient patients was not accompanied by a stoichiometric substitution of hypoxanthine and xanthine excretion rates. Allopurinol-related biochemical changes were similar in patients with either complete or partial HPRT deficiency. Renal function remained stable or improved with treatment. Three patients had urolithiasis during allopurinol treatment. In 2 patients, xanthine stones were documented and they required allopurinol dose adjustments aimed at reducing excessive oxypurine excretion rates. No allopurinol hypersensitivity reactions occurred. Neurologic manifestations were not influenced by allopurinol therapy. In conclusion, allopurinol is efficacious and generally safe for the treatment of uric acid overproduction in patients with HPRT deficiencies. Xanthine lithiasis, developing as a consequence of allopurinol therapy, should be preventable by adjustment of allopurinol dose.
Authors:
Rosa J Torres; Carmen Prior; Juan G Puig
Related Documents :
4979099 - Degradation of uric acid by certain aerobic bacteria.
8439489 - Familial hypouricaemia due to an isolated tubular defect of urate reabsorption.
6834539 - Lack of effect of salt intake on urinary uric acid excretion.
11473659 - Biochemical profile of idiopathic uric acid nephrolithiasis.
17914759 - Substituent effects on the energetics and aromaticity of aminomethylbenzoic acids.
7424639 - The uricosuric action of protein in man.
2153179 - Retinoic acid inhibits the production of collagenase by human epidermal keratinocytes.
161839 - Interference of l-alpha-aminooxy-beta-phenylpropionic acid with phenylalanine metabolis...
3082029 - Major operative trauma increases peripheral amino acid release during the steady-state ...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Metabolism: clinical and experimental     Volume:  56     ISSN:  0026-0495     ISO Abbreviation:  Metab. Clin. Exp.     Publication Date:  2007 Sep 
Date Detail:
Created Date:  2007-08-16     Completed Date:  2007-10-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375267     Medline TA:  Metabolism     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1179-86     Citation Subset:  IM    
Affiliation:
Division of Clinical Biochemistry, La Paz University Hospital, Madrid, Spain. rtorres.hulp@salud.madrid.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Allopurinol / administration & dosage,  adverse effects,  therapeutic use*
Antimetabolites / adverse effects,  therapeutic use
Child
Child, Preschool
Dose-Response Relationship, Drug
Follow-Up Studies
Humans
Hypoxanthine Phosphoribosyltransferase / genetics*
Infant
Kidney / physiopathology
Lesch-Nyhan Syndrome / drug therapy*,  genetics
Purine-Pyrimidine Metabolism, Inborn Errors / drug therapy*,  genetics,  metabolism,  physiopathology
Purines / metabolism
Retrospective Studies
Treatment Outcome
Uric Acid / blood,  urine
Chemical
Reg. No./Substance:
0/Antimetabolites; 0/Purines; 120-73-0/purine; 315-30-0/Allopurinol; 69-93-2/Uric Acid; EC 2.4.2.8/Hypoxanthine Phosphoribosyltransferase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The rs12255372(G/T) and rs7903146(C/T) polymorphisms of the TCF7L2 gene are associated with type 2 d...
Next Document:  Impact of markedly elevated serum lipoprotein(a) levels (> or = 100 mg/dL) on the risk of coronary h...